Local anesthetics block the generation and the conduction of nerve impulses,
presumably by increasing the threshold for electrical excitation in the nerve,
by slowing the propagation of the nerve impulse and by reducing the rate of
rise of the action potential. In general, the progression of anesthesia is related
to the diameter, myelination, and conduction velocity of affected nerve fibers.
Clinically, the order of loss of nerve function is as follows: pain, temperature,
touch, proprioception, and skeletal muscle tone.
Systemic absorption of local anesthetics produces effects on the cardiovascular
and central nervous systems. At blood concentrations achieved with normal therapeutic
doses, changes in cardiac conduction, excitability, refractoriness, contractility,
and peripheral vascular resistance are minimal. However, toxic blood concentrations
depress cardiac conduction and excitability, which may lead to atrioventricular
block and ultimately to cardiac arrest. In addition, myocardial contractility
is depressed and peripheral vasodilation occurs, leading to decreased cardiac
output and arterial blood pressure.
Following systemic absorption, local anesthetics can produce central nervous
system stimulation, depression, or both. Apparent central stimulation is manifested
as restlessness, tremors, and shivering, progressing to convulsions, followed
by depression and coma progressing ultimately to respiratory arrest. However,
the local anesthetics have a primary depressant effect on the medulla and on
higher centers. The depressed stage may occur without a prior excited stage.
A clinical study using 15 mL of 2% epidural mepivacaine at the T 9-10 interspace
in 62 patients, 20-79 years of age, demonstrated a 40% decrease in the amount
of mepivacaine required to block a given number of dermatomes in the elderly
(60-79 years, N=13) as compared to young adults 20-39 years).
Another study using 10 mL of 2% lumbar epidural mepivacaine in 161 patients,
19-75 years of age, demonstrated a strong inverse relationship between patient
age and the number of dermatomes blocked per cc of mepivacaine injected.
Pharmacokinetics
The rate of systemic absorption of local anesthetics is dependent upon the
total dose and concentration of drug administered, the route of administration,
the vascularity of the administration site, and the presence or absence of epinephrine
in the anesthetic solution. A dilute concentration of epinephrine (1:200,000
or 5 mcg/mL) usually reduces the rate of absorption and plasma concentration
of CARBOCAINE (mepivacaine) , however, it has been reported that vasoconstrictors do not significantly
prolong anesthesia with CARBOCAINE (mepivacaine) .
Onset of anesthesia with CARBOCAINE (mepivacaine) is rapid, the time of onset for sensory
block ranging from about 3 to 20 minutes depending upon such factors as the
anesthetic technique, the type of block, the concentration of the solution,
and the individual patient. The degree of motor blockade produced is dependent
on the concentration of the solution. A 0.5% solution will be effective in small
superficial nerve blocks while the 1% concentration will block sensory and sympathetic
conduction without loss of motor function. The 1.5% solution will provide extensive
and often complete motor block and the 2% concentration of CARBOCAINE (mepivacaine) will produce
complete sensory and motor block of any nerve group.
The duration of anesthesia also varies depending upon the technique and type
of block, the concentration, and the individual. Mepivacaine will normally provide
anesthesia which is adequate for 2 to 2 &fract12; hours of surgery.
Local anesthetics are bound to plasma proteins in varying degrees. Generally,
the lower the plasma concentration of drug, the higher the percentage of drug
bound to plasma.
Local anesthetics appear to cross the placenta by passive diffusion. The rate
and degree of diffusion is governed by the degree of plasma protein binding,
the degree of ionization, and the degree of lipid solubility. Fetal/maternal
ratios of local anesthetics appear to be inversely related to the degree of
plasma protein binding, because only the free, unbound drug is available for
placental transfer. CARBOCAINE (mepivacaine) is approximately 75% bound to plasma proteins.
The extent of placental transfer is also determined by the degree of ionization
and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter
the fetal blood from the maternal circulation.
Depending upon the route of administration, local anesthetics are distributed
to some extent to all body tissues, with high concentrations found in highly
perfused organs such as the liver, lungs, heart, and brain.
Various pharmacokinetic parameters of the local anesthetics can be significantly
altered by the presence of hepatic or renal disease, addition of epinephrine,
factors affecting urinary pH, renal blood flow, the route of drug administration,
and the age of the patient. The half-life of CARBOCAINE (mepivacaine) in adults is 1.9 to
3.2 hours and in neonates 8.7 to 9 hours.
Mepivacaine, because of its amide structure, is not detoxified by the circulating
plasma esterases. It is rapidly metabolized, with only a small percentage of
the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.
The liver is the principal site of metabolism, with over 50% of the administered
dose being excreted into the bile as metabolites. Most of the metabolized mepivacaine
is probably resorbed in the intestine and then excreted into the urine since
only a small percentage is found in the feces. The principal route of excretion
is via the kidney. Most of the anesthetic and its metabolites are eliminated
within 30 hours. It has been shown that hydroxylation and N-demethylation, which
are detoxification reactions, play important roles in the metabolism of the
anesthetic. Three metabolites of mepivacaine have been identified from human
adults: two phenols, which are excreted almost exclusively as their glucuronide
conjugates, and the N-demethylated compound (2´ 6´pipecoloxylidide).
Mepivacaine does not ordinarily produce irritation or tissue damage, and does
not cause methemoglobinemia when administered in recommended doses and concentrations.
Last reviewed on RxList: 3/4/2010
This monograph has been modified to include the generic and brand name in many instances.